Furthermore, our results report, to our knowledge, the longest follow-up for any clinical trial using perioperative FOLFIRINOX for resectable PDAC and are the first to report the impact of tumor molecular features, K17, and tissue-informed ctDNA on survival. Here, KRT17 is linked to neoplasm.